TransMedics Group, Inc. (TMDX) has seen a notable increase in its stock price, rising 5% on April 14, 2025, and marking a total gain of 53% since January lows. Daily flight volumes for TMDX in the first quarter rose by 20.3% compared to the previous quarter, suggesting potential revenue growth in line with this increase. Analysts are optimistic about the stock's trajectory, with predictions of a breakout above the $80 pivot point, and some anticipate a target price approaching $100. In contrast, Nuvation Bio, Inc. (NMAX) is facing challenges, currently down 90% from its peak, although some traders are observing its daily chart for potential opportunities above $27.50.